Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Certolizumab Pegol in Crohn's Disease
NCT00552344Phase 3Completed
- Sponsor
- UCB
- Start
- May 2008
- Primary completion
- Dec 2014
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 18
01
Overview
Phase 3, open-label, single-arm trial of certolizumab pegol in Crohn's disease, sponsored by UCB. Primary endpoints: Percentage of Subjects With at Least One Adverse Event (AE) up to 272 weeks and Percentage of Subjects With at Least One Serious Adverse Event (SAE) up to 272 weeks. Started May 2008; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00552344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00552344.